Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility by Chanchal Sur Chowdhury et al.
Sur Chowdhury et al. Arthritis Research & Therapy 2014, 16:R122
http://arthritis-research.com/content/16/3/R122RESEARCH ARTICLE Open AccessEnhanced neutrophil extracellular trap generation
in rheumatoid arthritis: analysis of underlying
signal transduction pathways and potential
diagnostic utility
Chanchal Sur Chowdhury1†, Stavros Giaglis1,2†, Ulrich A Walker3, Andreas Buser4, Sinuhe Hahn1* and Paul Hasler2*Abstract
Introduction: Neutrophil extracellular traps (NETs) have recently been implicated in a number of autoimmune
conditions, including rheumatoid arthritis (RA). We examined the underlying signaling pathways triggering
enhanced NETosis in RA and ascertained whether the products of NETosis had diagnostic implications or
usefulness.
Methods: Neutrophils were isolated from RA patients with active disease and from controls. Spontaneous NET
formation from RA and control neutrophils was assessed in vitro with microscopy and enzyme-linked immunosorbent
assay (ELISA) for NETosis-derived products. The analysis of the signal-transduction cascade included reactive oxygen
species (ROS) production, myeloperoxidase (MPO), neutrophil elastase (NE), peptidyl arginine deiminase 4 (PAD4), and
citrullinated histone 3 (citH3). NET formation was studied in response to serum and synovial fluid and immunoglobulin
G (IgG) depleted and reconstituted serum. Serum was analyzed for NETosis-derived products, for which receiver
operator characteristic (ROC) curves were calculated.
Results: Neutrophils from RA cases exhibited increased spontaneous NET formation in vitro, associated with
elevated ROS production, enhanced NE and MPO expression, nuclear translocation of PAD4, PAD4-mediated
citrullination of H3, and altered nuclear morphology. NET formation in both anti-citrullinated peptide antibody
(ACPA)-positive and -negative RA was abolished by IgG depletion, but restored only with ACPA-positive IgG.
NETosis-derived products in RA serum demonstrated diagnostic potential, the ROC area under the curve for
cell-free nucleosomes being >97%, with a sensitivity of 91% and a specificity of 92%. No significant difference
was observed between ACPA-positive and -negative cases.
Conclusions: Signaling elements associated with the extrusion of NETs are significantly enhanced to promote
NETosis in RA compared with healthy controls. NETosis depended on the presence of ACPA in ACPA-positive RA
serum. The quantitation of NETosis-derived products, such as cell-free nucleosomes in serum, may be a useful
complementary tool to discriminate between healthy controls and RA cases.* Correspondence: sinuhe.hahn@usb.ch; paul.hasler@ksa.ch
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A novel feature of the biology of polymorphonuclear gran-
ulocytes (PMNs) is their ability to generate neutrophil
extracellular traps (NETs) [1] via a distinct process of cell
death termed NETosis [2]. NETs consist of extruded
chromosomal DNA decorated with granular components
that include antimicrobial peptides and proteases. The
molecular pathways leading to NETosis encompass cal-
cium mobilization, generation of reactive oxygen species
(ROS), nuclear delobulation involving the enzymatic activ-
ities of myeloperoxidase (MPO) and neutrophil elastase
(NE), and chromatin modification via the citrullination of
histones by peptidyl arginine deiminase 4 (PAD4) [2-6].
A number of studies have implicated NETs in the
etiology of autoinflammatory or autoimmune conditions
such as preeclampsia, Felty syndrome, systemic lupus ery-
thematosus (SLE), multiple sclerosis, and, most recently,
rheumatoid arthritis (RA) [7-13]. In the context of RA,
these findings are especially interesting, as NETs have
been proposed to contribute to the generation of anti-
citrullinated protein antibody (ACPA) autoantigens, and
may also be a target for autoantibodies [13,14]. PMNs iso-
lated from RA patients showed an increased propensity to
undergo spontaneous and LPS-induced NETosis, which
was in part mediated by TNF and IL-17 and could be
inhibited by blocking NADPH oxidase or PAD4. Whereas
the citrullinated autoantigens vimentin and α-enolase
were expressed on NETs from RA PMNs, antibodies to
the former were able to induce NET formation by healthy
control PMNs [13,14].
As we had previously detected significantly increased
concentrations of cell-free DNA in the sera of RA patients
compared with healthy controls, we were intrigued
whether the provenance of this material involved NETosis
[15]. The premise for the current investigation was that a
link between circulating cell-free DNA levels and NETs
has previously been made in a number of conditions,
including preeclampsia, sepsis, cancer, thrombosis, or even
storage of blood-transfusion products [16-19].
In view of these findings and reports on the complex in-
volvement of neutrophil NETs in autoimmunity, we sought
to investigate the NETotic response of PMNs in RA, with
particular regard to the underlying signal-transduction




All patients fulfilled the American College of Rheuma-
tology classification criteria for RA, or for systemic
lupus erythematosus, respectively. Healthy volunteers,
matched for gender and age, were recruited at the
hospitals or at the Blood Bank of the Swiss Red Cross,
Basel. Inclusion criteria for healthy controls were fairgeneral condition, age ≥28 and ≤70 years, and for blood
donors fulfilling national criteria for blood donation.
Exclusion criteria were current or previous systemic
autoimmune disease, asthma and reconvalescence after
major illness, surgery, current medication with corti-
costeroids, immunosuppressive agents, and malignant
neoplasia or chemotherapy within 5 years before
recruitment for the study. RA cases had a DAS ≥2.6,
were from age ≥27 to ≤70 years, and had no other
systemic autoimmune disease, including ankylosing
spondylitis and psoriatic arthritis.
Exclusion criteria were corticosteroids ≥40 mg equiva-
lent of prednisone daily, and those mentioned earlier for
healthy controls. Informed, written consent was obtained
from all subjects in the study, which was approved by
the Cantonal Ethical Review Boards of Aargau-Solothurn
and Basel/Basel-Land, Switzerland.
Preparation of plasma and serum
Plasma and serum were collected and processed as
described previously [15]. Samples were studied immedi-
ately or stored at −80°C until analysis.
Cell isolation
PMNs were isolated with Dextran-Ficoll density centri-
fugation [8]. Cell viability was 96% to 98%, with a purity
of >95% PMNs. Neutrophils seeded in 24-well plates
were allowed to settle for 1 hour at 37°C under 5% CO2
before further experimentation.
Cell-free DNA isolation and quantification
Cell-free DNA extracted from 850 μl plasma or serum by
using the QIAamp Circulating Nucleic Acid Kit (Qiagen,
Valencia, CA, USA) was quantified by TaqMan real-time
PCR (StepOne Plus Real-Time PCR System, Applied Bio-
systems, Foster City, CA, USA) specific for the glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) gene [15].
Detection of neutrophil elastase (NE), myeloperoxidase
(MPO), and cell-free nucleosomes
The concentrations of neutrophil elastase (NE) and mye-
loperoxidase (MPO) were measured with sandwich ELISA
(Elastase/a1-PI Complex ELISA Kit, Calbiochem/EMD,
Gibbstown, NJ, USA) and the human (MPO ELISA Kit,
Hycult Biotech, Plymouth Meeting, PA, USA) respectively.
Nucleosomes were measured by using the Human Cell
Death Detection ELISAPLUS (Roche Diagnostics, Basel,
Switzerland). Cell-culture supernatants were incubated with
DNaseI (10 U for 5 minutes) (Roche Diagnostics) before
analysis [20].
MPO/DNA complex detection
MPO is present on extruded NETs. To detect such
structures, NET-associated MPO/DNA complexes were
Table 1 Demographics and patient population
characteristics versus healthy blood donors
Controls RA Statistics
Age 50.34 ± 1.5 53.03 ± 1.5 P = 0.214
Gender (F/M) 24/32 24/8 -
DAS28 n.a. 3.07 ± 1.12 -
Bone erosion (pos/neg) n.a. 22/10 -
Serum ACPA (pos/neg) n.a. 20/12 -
Serum RF (pos/neg) n.a. 19/13 -
Serum ANA (pos/neg) n.a. 21/11 -
ESR (mm/h) n.a. 16.8 ± 13.1 -
CRP (mg/L) n.d. 6.9 ± 5.2 -
PBMC (cells/μl) 1,961 ± 81.69 1513 ± 75.90 P < 0.0001
PMN (cells/μl) 3,641 ± 149.7 4575 ± 546.0 P = 0.021
Therapy (yes/no) n.a. 31/1 -
DMARDs (yes/no) n.u. 27/5 -
Biologics (yes/no) n.a. 30/2 -
F, female; M, male; DAS28, disease activity score; n.a., not applicable; pos,
positive; neg, negative; ACPA: anti-citrullinated protein antibodies; RF, rheumatoid
factor; ANA, antinuclear antibody; ESR, erythrocyte sedimentation rate; CRP,
C-reactive protein; n.d., not determined; PBMC, peripheral blood mononuclear
cell; PMN, polymorphonuclear leukocyte; DMARD, disease-modifying
antirheumatic drug; n.u., not used.
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brief, NET-associated MPO in serum or culture super-
natant was captured by using the coated 96-well plate of
the human MPO ELISA Kit, (Hycult Biotech), after which
the NET-associated DNA backbone was detected by using
the detection antibody of the Human Cell Death Detec-
tion ELISAPLUS (Roche Diagnostics).
PAD4/DNA-complex detection
To detect the presence of PAD4 on extruded NETs in
culture supernatants after spontaneous NETosis, cell-free
PAD4/DNA complexes were quantified by using a modi-
fied capture ELISA, akin to that described for MPO
earlier. In brief, cell-free PAD4 was captured by using the
coated 96-well plate of a commercial human PAD4 ELISA
(USCN Life Science, Inc., Wuhan, China), and associated
DNA was detected by using Human Cell Death Detection
ELISAPLUS kit (Roche Diagnostics).
ROS generation analysis
ROS was measured by using a 2′,7′-dichloro dihydrofluor-
escein diacetate (DCFH-DA) assay [22]. The 5 × 105 cells
in a final volume of 500 μl were incubated for 30 minutes
with 25 μM DCFH-DA (Sigma-Aldrich, St. Louis, MO,
USA). Fluorescence was measured with flow cytometry
(FACSCalibur; BD Biosciences, San Jose, CA, USA).
Fluorescence and scanning electron microscopy
The 5 × 104 cells isolated PMNs seeded on poly-L-lysine-
coated coverslips (BD Biosciences) were stimulated with
phorbol-12-myristate-13-acetate (PMA, Sigma-Aldrich)
for 90 minutes and dehydrated with a graded ethanol
series (30%, 50%, 70%, 100%) [8], coated with 2-nm plat-
inum, and analyzed with a Nova NanoSEM 230 scanning
electron microscope (FEI Co., Hillsboro, OR, USA). PMNs
were incubated for 10 minutes with 5 μM Sytox Green
dye (Invitrogen Life Technologies, San Diego, CA, USA)
for assessment of NETs with an Axiovert fluorescence
microscope (Carl Zeiss) coupled to a Zeiss AxioCam
color CCD camera (Carl Zeiss Microimaging, Oberkoch,
Germany) [8,23].
Immunohistochemical staining and quantification of NETs
The 5 × 104 isolated PMNs were seeded on poly-L-
lysine-coated glass coverslips (BD Biosciences, San Jose,
CA, USA) in tissue-culture wells and allowed to settle
before stimulation, as described earlier. Coverslips were
rinsed with ice-cold HBSS and the cells fixed with 4%
paraformaldehyde and blocked overnight (HBSS with
10% goat serum, 1% BSA, 0.1% Tween20, and 2 mM
EDTA) at 4°C. NETs were detected with rabbit anti-NE
(Abcam, Cambridge, MA, USA), rabbit anti-MPO
(Dako, Glostrup, Denmark), two different rabbit anti-
PAD 4 (Abcam), mouse anti-PAD4 (Abcam), mouseanti-histone H1 + core proteins (EMD Millipore, Billerica,
MA, USA), and rabbit anti-citrullinated histone H3
(citH3, Abcam). Secondary antibodies were goat anti-
rabbit IgG AF555, goat anti-rabbit IgG AF488 (Invitrogen
Life Technologies, San Diego, CA, USA), and goat anti-
mouse IgG AF647. DNA was stained with 4′,6-diamidino-
2-phenylindole (DAPI, Sigma-Aldrich), and NETs were
visualized by using a Zeiss Axioplan 2 Imaging fluores-
cence microscope in conjunction with a Zeiss AxioCam
MRm monochromatic CCD camera and analyzed with
Axiovision 4.8.2 software (Carl Zeiss). A minimum of 20
fields (at least 1,000 PMNs) per case was evaluated for
MPO/NE and DNA co-staining; nuclear phenotypes and
NETs were counted and expressed as percentage of the
total number of cells in the fields.
RA serum depletion, IgG purification, and quantification
of NETs
After three washes with PBS, 200 μl protein G agarose
(Pierce Biotechnology Inc, Rockford, IL, USA) was incu-
bated with 200 μl ACPA + and ACPA- RA or control
serum diluted in an equal volume of phenol red-free RPMI
1640 medium overnight at 4°C. The serum/protein G
agarose mixture was centrifuged at 2,500 g for 5 minutes,
and the supernatant (IgG-depleted serum) was carefully
transferred into a new Eppendorf microcentrifuge tube.
The protein G agarose pellet was gently washed 3 times
with 500 μl ddH2O, and the bound antibody was released
by the addition of 50 μl 0.1M glycine pH 2–3, and
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All protein concentrations were determined with the MN
Protein Quantification Assay (Macherey-Nagel GmbH,
Düren, Germany), and isolation of IgG was verified with
Coomassie staining of SDS-PAGE.
Neutrophils from healthy donors (n = 3) were isolated
and cultured for 2 hours in 96-well culture dishes (Thermo
Fischer Scientific, Waltham, MA, USA), supplemented
with: serum, depleted serum, and purified IgG from ACPA-
positive RA patients (n = 3), ACPA-negative RA patients
(n = 3), and healthy individuals (n = 3) to a final concentra-
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Figure 1 RA-derived PMNs exhibited increased spontaneous NETosis
representation of the time-course design for studying in vitro spontaneous
for neutrophil elastase (NE) (green) and DAPI (blue). Magnification: 20×; sca
culture supernatant by ELISA. (D) Quantification of NET-associated MPO/DN
progression of NET formation is observed in RA versus control PMNs. (E) C
immunohistochemistry for NE and DAPI. (F) Steady-state (T1) RA-derived PM
progressed rapidly to a NETotic spread phenotype during in vitro culture. D
****P < 0.0001. All data are representative of at least six independent experNETs were quantified after IHC staining with mouse
anti-human MPO antibody (Abcam) and rabbit anti-
human citH3 antibody (Abcam), or the respective isotype
controls, followed by incubation with goat anti-mouse IgG
AF555 and goat anti-rabbit IgG AF488 (Invitrogen Life
Technologies). DNA was counterstained with 4′,6-diami-
dino-2-phenylindole (DAPI, Sigma-Aldrich). NETs were
visualized by using an Olympus IX81 motorized epifluor-
escence microscope (Olympus America Inc., Center Val-
ley, PA, USA) in conjunction with an Olympus XM10
monochromatic CCD camera (Olympus) and analyzed
with the Olympus CellSens Dimension software (Olympus).3 
h 
T3
T1      T2      T3      T1      T2      T3 


























T1      T2      T3      T1      T2      T3 























T1     T2      T3      T1      T2     T3 




















T1     T2      T3      T1      T2     T3 






















and elevated levels of NET-component release. (A) Schematic
NET release. (B) Detection of in vitro NETosis by immunohistochemistry
le bar, 50 nm. (C) Concentration of cell-free nucleosomes in PMN
A complexes. These assays indicate that more-rapid and extensive
hanges in PMN nuclear morphology during NETosis detected with
Ns exhibited a greater proportion of delobulated/diffused cells, and
ata are presented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001;
iments.
Figure 2 (See legend on next page.)
Sur Chowdhury et al. Arthritis Research & Therapy 2014, 16:R122 Page 5 of 14
http://arthritis-research.com/content/16/3/R122
(See figure on previous page.)
Figure 2 Increased expression of NET-associated signaling elements and nuclear localization of PAD4, citrullination of histone H3 in
RA-derived PMN, and possible extrusion of PAD4 on NETs. Baseline ROS levels, measured with flow cytometry, were higher in RA-derived
PMNs than in control PMNs (A). Quantitative real-time PCR analysis of NE mRNA (B) and MPO mRNA expression (C), as well as Western blot
analysis of MPO protein levels (D), indicated that the levels of these two components required for NETosis were elevated in RA-derived PMNs.
Total PAD4 protein (E) or PAD4 mRNA expression levels (F) did not indicate any significant difference between control and RA-derived PMNs.
(G) Quantification of PAD4 protein levels in cytoplasmic and nuclear fractions of PMNs from healthy controls and RA patients. Nuclear levels of
PAD4 were significantly increased in RA patients, whereas the cytoplasmic levels were lower compared with the healthy control PMNs. (H)
Elevated citrullinated histone H3 levels in RA PMN extracts detected with Western blot. (I) Co-localization of citrullinated histone H3 (green) with
histone components detected with a pan-histone antibody (red), spread over the entire NET surface (blue). Magnification: upper panel 20×, scale bar,
50 nm; lower panel 63× scale bar, 10 nm. (J) Extracellular localization of PAD4 (red) on extruded NETs by multicolor fluorescent immunohistochemistry.
NET DNA is stained blue (DAPI), and histones (panH) are stained green. Magnification, 20×; scale bar, 50 nm (K). Detection of PAD4/cell-free DNA
complexes in the culture supernatants of isolated PMN undergoing spontaneous NETosis. Higher levels of these complexes were detected in
RA-derived PMN cultures. Time points correspond to those of Figure 1A. Data are represented as mean ± SEM. **P < 0.01; ***P < 0.001; ****P < 0.0001;
n.s., statistically not significant. All data are representative of at least six independent experiments.
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to 1,000 PMNs) per case was evaluated for MPO/citH3 and
DNA co-staining through ImageJ analysis software (National
Institutes of Health Image Processing, Bethesda, MD,
USA); nuclear phenotypes and NETs were determined,
counted, and expressed as percentage of the total area of
cells in the fields [24].
Protein isolation and Western blot analysis
Total protein was isolated with NucleoSpin TriPrep kit
(Macherey-Nagel) from 3 × 106 PMNs. Proteins from the
nuclear and cytoplasmic fractions were isolated by using
the Nuclear and Cytoplasmic Protein Extraction Kit
(Thermo Scientific). Western blotting was performed
by using AnykD Mini-PROTEAN TGX Gels (Biorad,
Hercules, CA, USA) and nylon/nitrocellulose mem-
branes (Biorad). Primary and secondary antibodies used
were: rabbit anti-PAD4 (Abcam), rabbit anti-MPO (Cell
Signalling Technologies, Beverly, MA, USA), mouse
anti-β-Actin (Sigma-Aldrich), goat anti-Mouse and/or
anti-Rabbit, human anti-HRP (Southern Biotech). HRP
activity was detected by using SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific). Equal
loading was verified by using beta-actin or histone H3,
when appropriate. Western blots of citrullinated H3
(citH3) protein were performed according to Shechter
et al. [25]. Densitometric analysis and protein quantifi-
cation of the Western blots was performed by using the
ImageJ software.
RNA isolation and quantitative real-time PCR
Total RNA was isolated by using RNeasy Mini Kit (Qiagen).
TaqMan real-time quantitative RT-PCR was performed by
using the Applied Biosystems StepOne Plus cycler (Applied
Biosystems) and TaqMan Gene Expression Assay primer/
probe sets (Applied Biosystems) for ELANE (HS00236952_
m1), MPO (HS00924296_m1), PADI4 (HS00202612_m1),
and β2-microglobulin B2M (HS99999907_m1). Data were
normalized by using the housekeeping gene B2M, after aselection procedure involving six different endogenous
reference genes, as suggested in the MIQE guidelines [26].
Relative values were calculated with 2−DDCt analysis [27].Statistical analysis
All data are presented as mean ± SEM. Descriptive statis-
tics for continuous parameters consisted of median and
range, and categoric variables were expressed as percent-
ages. Comparisons between patients and healthy controls
were by the Mann–Whitney U test with a Welch posttest
correction. Statistical significance in multiple comparisons
was by one-way analysis of variance (ANOVA) with a
Dunn posttest correction. P < 0.05 was considered statisti-
cally significant.
Receiver operating characteristic (ROC) curves were
calculated, and the area under the curve (AUC) with
corresponding standard errors of means was calculated.
Data were processed in GraphPad Prism version 5.0b for
MacOSX (GraphPad Software Inc., San Diego, CA,
USA). Analysis of covariance (ANCOVA) was conducted
with SPSS version 21.0 statistical software (IBM SPSS
Inc., Chicago, IL, USA). Additional professional statis-
tical assistance was provided by A. Schoetzau, Basel.Results
RA-derived PMN exhibit increased spontaneous NETosis
Details of the RA study group and healthy control group
are described in Table 1 and Additional file 1.
As in very recent observations [13], we observed that
RA-derived PMNs underwent greater degrees of NETosis
than did control PMNs in vitro (data not shown). To study
this facet in more detail, we examined the kinetics of
spontaneous NET extrusion, for which purpose, PMNs
isolated from peripheral blood samples were allowed to
settle for 1 hour and then cultured for a period of up to
3 hours in vitro (Figure 1A), NETs being detected by im-
munohistochemistry for neutrophil elastase (NE) and DAPI
(4′,6-diamidino-2-phenylindole) (Figure 1B). In addition,
lobulated
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Figure 3 (See legend on next page.)
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Figure 3 Increased NETotic response of RA-derived PMNs to PMA. (A) Scanning electron micrographs of NETs induced by PMA (25 nM)
indicate the excessive NETotic response of RA-derived PMN. Scale bar, 20 nm. (B) Assessment of NETs induced by PMA treatment by fluorescent
immunohistochemistry for MPO (red) and DAPI (blue), indicating the increased response of RA PMNs to PMA (25 nM). Magnification, 20×; scale
bar, 50 nm. (C) Analysis of the nuclear phenotype indicated a vast decrease in delobulated/diffused RA PMN nuclei after treatment with PMA and
rapid increase in the NETotic-spread phenotype. (D) Release of cell-free nucleosomes after PMA treatment is abrogated by chloramidine, a PAD4
inhibitor. (E) Increased nuclear localization and concomitant decrease in cytoplasmic PAD4 protein levels after PMA treatment, with a clear
tendency for an increased responsiveness to the PMA stimulus by RA PMN. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n.s., statistically not
significant. All data are representative of at least four independent experiments.
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these cultures by determining the concentration of cell-free
nucleosomes in the respective supernatants (Figure 1C),
specifically their association with myeloperoxidase (MPO),
indicative of the NETotic origin of this material [2,21]
(Figure 1D). We also measured NET-associated MPO en-
zymatic activity by using tetramethylbenzidine (TMB) as a
substrate (data not shown). The results clearly indicate
that RA-derived PMNs generated NETs more rapidly, to a
greater magnitude, and more extensively than did control
healthy PMNs, which was particularly evident at the 3-hour
stage of in vitro culture (Figure 1B to D). Accounting for
variances in PMN counts, the difference between the
healthy control and RA subjects remained highly significant
in an analysis of covariance (ANCOVA) of the nucleosome
assay (P < 0.001).
During NETosis, the morphology of the PMN nucleus
changes from the familiar lobulated to a diffused and then
to a spread phenotype (Figure 1E) [28]. By examining and
enumerating these features, it was observed that at base-
line (T1), the nuclei from healthy control PMNs were
predominantly lobulated, whereas in this instance, the
majority of RA-derived PMN nuclei exhibited a delobu-
lated or diffused nuclear phenotype (Figure 1F). In RA-
derived PMNs, this delobulated population decreased
over time, giving rise to NETotic cells with a spread
phenotype (Figure 1F). In contrast, in normal PMNs, we
noted a steady progression in the proportion of delobu-
lated cells (Figure 1F). The spontaneous progression of
nuclei to the NETotic-spread phenotype was more pro-
nounced in RA than in normal PMNs, a feature most
evident after 3 hours (T3) (Figure 1F).RA-derived PMNs demonstrate increased expression of
NET-associated signaling elements, nuclear localization of
PAD4, and augmented H3 citrullination
NETosis has been shown to depend on a number of bio-
chemical signaling elements, among which are the gen-
eration of ROS by nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase, the action of NE in com-
bination with MPO, and histone citrullination by PAD4
[2,3,5]. RA-derived PMNs exhibited increased basal intra-
cellular ROS levels (Figure 2A), as well as increased levelsof NE (Figure 2B) and MPO (Figure 2C and D), as deter-
mined with real-time PCR and/or Western blotting.
Surprisingly, neither PAD4 mRNA expression nor
PAD4 levels in total cellular protein showed any discern-
ible difference between RA and control PMNs (Figure 2E
and F, respectively). Because PAD4 translocates to the
nucleus on PMN activation [4,29], where it citrullinates
histone proteins, such as H3, we examined its presence
in nuclear and cytoplasmic PMN fractions. Compared
with control PMNs, PAD4 was preferentially located in
the nucleus of RA-derived PMNs (Figure 2G). The nu-
clear presence of PAD4 was associated with increased
citrullinated histone H3 (citH3) levels with Western blot
analysis in PMNs from RA cases compared with controls
(Figure 2H). Furthermore, citrullinated histone H3 could
be readily detected on NET structures (Figure 2I).Potential extracellular localization of PAD4 on NETs
Because we observed elevated nuclear translocation of
PAD4 in RA PMNs, we examined whether this enzyme is
extruded into the extracellular environment during NETo-
sis. Unfortunately, the visualization of such an event by
fluorescence immunohistochemistry proved to be difficult
with a variety of commercially available antibodies, and we
obtained only rudimentary evidence for the presence of
PAD4 on NETs by this means (refer to Figure 2J).
We were, however, able to detect PAD4/cell-free DNA
complexes readily in culture supernatants from isolated
PMNs, the levels of which were increased in cases with RA
(Figure 2K). It is, therefore, quite probable that PAD4 is asso-
ciated with NETs structures after aberrant NETosis in RA.PMNs from RA patients present an enhanced NETotic
response to PMA, and normal PMNs are strongly affected
by RA serum and synovial fluid
In autoinflammatory or malignant conditions, such as
SLE or cancer, an elevated NETotic response of PMNs
to an external activation signal has been shown [9,13].
In our experiments, we noted that when RA-derived
PMNs were treated with PMA, they responded far more
vigorously with regard to NETosis than did controls, as
detected by SEM and fluorescence microscopy (Figure 3A
and B, respectively).
Figure 4 (See legend on next page.)
Sur Chowdhury et al. Arthritis Research & Therapy 2014, 16:R122 Page 9 of 14
http://arthritis-research.com/content/16/3/R122
(See figure on previous page.)
Figure 4 Influence of RA serum and synovial fluid on normal PMNs. (A) Incubation of healthy donor PMNs with serum (Se) from healthy
donors or from RA patients, synovial fluid (SF) from patients with noninflammatory osteoarthritis (OA) or synovial fluid from RA patients.
Immunohistochemical analysis of four main components of NETs (NE, MPO, PAD4, and citH3) revealed that RA-derived serum and SF enhanced
NETosis in normal PMN compared to healthy control serum or noninflammatory OA SF. PAD4 (white arrowheads) and citH3 (empty arrowheads)
colocalize with unmodified histones on NETs. Magnification, 20×; scale bars, 50 nm. (B) Release of cell-free nucleosomes during in vitro culture by
PMNs from healthy controls incubated with control serum, RA serum, OA SF or RA SF, or PMA. Data are represented as mean ± SEM. *P < 0.05;
**P < 0.01. (C) Increased ROS generation during in vitro culture by PMNs from healthy controls incubated with control serum, RA serum, OA SF or
RA SF, or PMA. Data are presented as mean ± SEM. (D) Release of cell-free nucleosomes during in vitro culture by PMNs from healthy controls,
ACPA-positive and ACPA-negative RA patients incubated with serum (Se +), IgG-depleted serum (Se -), or serum reconstituted with their respective
eluted IgG, or with PMA. Data are presented as mean ± SEM. *P < 0.05; ***P < 0.001; ****P < 0.0001; n.s., statistically not significant. All data are
representative of at least four independent experiments in Figures 4A–C, and 3 in 4D.
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derived PMNs exhibited a larger decrease in cells with a
delobulated phenotype and a greater progression toward a
NETotic-spread nuclear phenotype than control PMNs
(Figure 3C), a feature accompanied by excessive release of
cell-free nucleosomes in culture supernatants (Figure 3D).
PMA appears to activate PAD4, as it enhanced transloca-
tion from the cytoplasm to the nucleus (Figure 3E). The
stimulatory effect of PMA on the release of nucleosomes
into the supernatant was abrogated by Cl-amidine, a chem-
ical inhibitor of PAD4, indicating that PAD4 signaling is ne-
cessary for NETosis induced by PMA [4,30] (Figure 3D).
These data indicate that PMNs in RA are susceptible to
increased NETosis after stimulation by a secondary signal,
such as that mediated by PMA.
Because SLE sera and RA sera and synovial fluid (SF)
have been shown to confer an increased NETotic response
[9,13], we examined whether RA-derived sera or SF
exerted similar effects on normal PMNs. As noninflamma-
tory controls, we used healthy serum or osteoarthritis SF.
Both RA sera and SF induced a pronounced increase in
NETosis, which was paralleled by an increase in the
nucleosome content of the supernatant (Figure 4A,B), as
well as in ROS production (Figure 4C) when compared
with healthy serum or osteoarthritis SF, respectively.
To assess whether antibodies participate in the effects
of RA serum on normal PMNs, we depleted IgG from
serum of ACPA-positive and -negative RA patients and
healthy controls. Compared with nondepleted sera, IgG
depletion of both ACPA-positive and -negative sera
markedly reduced NET induction to levels of normal
serum (Figure 4D). Whereas the reconstitution of ACPA-
negative IgG to serum did not increase NET formation
significantly compared with controls, it was practically
reversed to the original value in the ACPA-positive cases.
This indicates a prominent role for ACPA in the induction
of NETs in ACPA-positive RA, while suggesting that an
alternative mechanism is responsible for the increased
NETosis in ACPA-negative RA patients.
These data are in accordance with recent findings that
RA-derived serum and SF induce NETosis in normalPMNs, and that ACPA and also IgM RF are to a large
part responsible for this effect [13,14].
Serum from RA patients shows elevated levels of the
principal components of NETs, indicating enhanced NET
extrusion during clot formation, which has potential
clinical utility
As we had previously observed increased levels of cell-free
DNA (cfDNA) in RA sera [15], we determined whether
this resulted from enhanced NETosis, and whether this
could have diagnostic applications. cfDNA concentrations
were indeed significantly higher in serum samples from
RA cases compared with age-matched healthy control sera
(Figure 5A). In parallel, the concentrations of cell-free nu-
cleosomes, NE, and MPO were significantly elevated in
RA serum compared with control sera (Figure 5B to D).
The association of a significant fraction of MPO with
markedly elevated cell-free nucleosomes in RA serum,
which constitute a main component of NETs (Figure 5E),
clearly suggests that NETosis is indeed the source of nu-
cleosome material present in RA serum [21].
Since there was no significant elevation of these parame-
ters in simultaneously obtained plasma samples that were
processed immediately, these data demonstrate a propen-
sity for RA PMN to undergo increased NETosis during
coagulation (Figure 5A to E).
To ascertain whether NET-associated serum compo-
nents could be diagnostically useful, we conducted ROC
analyses. For serum cell-free nucleosomes, this yielded the
surprisingly high AUC value of 0.97 (see Additional file 2
and Figure 5F). Of interest is that no significant difference
was found in this value regardless of whether the RA cases
were ACPA positive or not (Figure 5G), although a slight
trend for serum nucleosome levels was higher in ACPA-
positive cases than in ACPA-negative cases (Figure 5H).
The AUC for serum nucleosomes was significantly higher
than for any of the other parameters examined (Figure 5I
to K). With the cut-off set at 0.78, the ROC AUC trans-
lates into a sensitivity of 91%, with a specificity of 92% for
differentiating between RA cases and healthy controls.
Figure 5 (See legend on next page.)
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Figure 5 Elevated serum levels of NET components in RA patients have potential clinical utility. (A) Cell-free DNA levels in plasma and
serum from healthy matched blood donors (n = 41) and patients with RA (n = 32) determined with real-time PCR. (B) Cell-free nucleosome levels
in plasma and serum from healthy donor controls and patients with RA, determined with ELISA. (C) Determination of NE protein concentrations
in plasma and serum from healthy donors and patients with RA, as assessed with sandwich ELISA. (D) MPO concentrations in plasma and serum
from healthy donors and patients with RA, as determined with sandwich ELISA. (E) NET-associated MPO/DNA complexes quantified by using a
modified capture ELISA. In contrast to the serum levels, none of the plasma levels of these NET components attained statistical significance
(Figure 5A to E). (F) ROC analysis of cell-free nucleosomes in serum of patients with RA and healthy controls. (G) Detail of cell-free nucleosome
ROC curve with groups of ACPA + and ACPA- RA cases and (H) scatterbox and whisker plots with individual values for control, ACPA + and
ACPA- groups. The ROC curve analysis of other NET components, cell-free DNA (I), NE (J), and MPO (K), was not as conclusive as that for cell-free
nucleosomes. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n.s., statistically not significant.
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values of 14 cases with SLE showed a slight, but statisti-
cally significant increase (Additional file 2). This translated
into an ROC AUC of 0.7639 (see Additional file 3),
which is below the clinically useful value for diagnostic
purposes.
Discussion
Although PMNs figure prominently in the joint effu-
sions and inflamed synovial tissue of RA patients [31],
the potential roles of NETotic events in the pathophysi-
ology of this disorder have only recently become a focus
of attention [13,14]. These studies indicated that RA-
derived PMNs were more prone to undergo NETosis,
and that NETs themselves could contribute to the
generation of auto-antigens (ACPAs) or be the target of
auto-antibodies [13,14].
Our studies, performed independently at a time similar
time to these, corroborate that NETosis is enhanced in
RA, confirming a possible fundamental role of this
phenomenon in the underlying etiology of RA. In
addition, we extended these observations by examining for
changes in the underlying signal-transduction cascade
required for the induction of NETosis. The results show
that the propensity of circulatory PMNs in RA patients to
undergo NETosis is associated with elevations in members
of this cascade, including increased intracellular ROS pro-
duction, enhanced expression of NE and MPO, increased
nuclear translocation of PAD4, and citrullination of his-
tones, notably H3. Consequently, these and other key
NETotic pathway elements [6] could serve as potential
therapeutic targets for interventional strategies.
Furthermore, by examining kinetic changes during ex-
tended in vitro culture, different nuclear morphometric
characteristics were observed in PMNs from RA cases,
with a lower proportion of the classic lobulated pheno-
type, coupled with a much higher proportion of delobu-
lated cells at the initial time point. Unlike in controls, in
which an increase in this population was noted over time,
this latter population decreased during in vitro culture in
RA PMNs. RA PMNs also progressed more rapidly and
extensively to a NETotic-spread phenotype than controls,a finding confirmed by analysis of culture supernatants for
the products of NETosis.
Akin to that observed in an array of other pathologic
conditions ranging from preeclampsia and SLE to cancer
and RA [8,9,12,13,17], PMNs from RA patients exhibited
an increased response to further stimulation (for instance,
by treatment with IL-8, the phorbol ester PMA, or with
LPS). This response is in part mediated via the action of
PAD4, as the effect of PMA could be significantly reduced
by treatment with Cl-amidine, an inhibitor of PAD4 [30].
In addition, PMA treatment led to an increased nuclear
localization of this enzyme, where it presumably could
catalyze a more-extensive citrullination of histone pro-
teins, thereby speeding the induction of NETosis.
Although our data are preliminary, they do suggest that
PAD4 is extruded onto the NETs during NETosis, as
detected with ELISA technology and, to a lesser extent, by
fluorescence microscopy. Such an occurrence would have
important implications for the development of anti-PAD4
autoantibodies observed in cases with RA [32]. Because
the presence of such antibodies precedes the develop-
ment of RA, our data provide further support that NETs
may contribute to the underlying etiology of RA, and
may be a relatively early event. As the presence of such
anti-PAD4 antibodies has been shown to enhance the
enzymatic activity of PAD4 in an extracellular environ-
ment by reducing the calcium requirement [33], their
combination with NETs-associated PAD4 could lead to
prodigious quantities of citrullinated autoantigens. In
addition, the extracellular presence of PAD4 on NETs
may further promote the prodigious generation of
citrullinated antigens, because molecular structures in-
volving the attachment of enzymes to DNA lattices have
been shown to increase their catalytic activity enor-
mously, and thereby form the basis of nano-machines
or nano-factories, generating such autoantigens [34].
Although these findings must be verified, and it remains
to be ascertained whether extracellular NETs-associated
PAD4 is active, these data do support and extend recent re-
ports indicating that NETs can be a source for citrullinated
autoantigens, and that they react with ACPA or anti-PAD4
antibodies [13,14,35]. Taken together, these data provide
further evidence concerning a key role for PAD4 in the
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for the efficacy of PAD4 inhibitor chloramidine in reducing
disease symptoms in collagen-induced rat and murine arth-
ritis models for RA [36].
It recently was reported that ACPA or IgM RF led to
potent increases in NET formation compared with control
IgG [13]. In our IgG-depletion experiments on ACPA-
positive and -negative RA cases, we observed a marked
reduction of NET induction to control levels in both cases,
whereas reconstitution of serum with IgG gained from
depletion almost completely restored NET induction in
the ACPA-positive cases. However, in the ACPA-negative
cases, no significant increase followed reconstitution.
These results support the notion that ACPAs are import-
ant inducers of NET formation in ACPA-positive RA
cases, and indicate that other mechanisms, such as IgG
complexes similar to those involved in NET induction in
SLE [8], are operative in ACPA-negative RA. Both mecha-
nisms could lead to a common distal mechanism of induc-
tion of arthritis.
The observation that the coagulation of blood samples
from RA patients during serum preparation triggers ex-
tensive NETosis, evident by increased concentrations of
cell-free DNA, nucleosomes, or nucleosome/MPO com-
plexes, may have unexpected clinical ramifications. With
a sensitivity of 91% and a specificity of 92%, it is possible
that the assessment of serum cell-free nucleosomes may
serve to distinguish suspected RA patients from healthy
controls with a high degree of specificity. It is of interest
that this aspect was not significantly influenced by the
ACPA status of the RA patients. As such, this assay may
be a useful complementary test to perform in conjunc-
tion with current ACPA or RF assays, not only to extend
diagnostic accuracy, but also to assist in detecting RA in
cases that are either ACPA or RF negative. Similar NET
induction by ACPA-positive and -negative RA sera and its
abrogation by IgG depletion, as discussed earlier, supports
the functional aspect of the nucleosome measurement in
RA serum.
In a preliminary series of SLE sera, a small and not
statistically significant increase of cell-free nucleosomes
over normal controls was observed, indicating a slightly
elevated propensity for PMNs from SLE patients to
undergo NETosis. This was, however, nowhere near the
range seen in RA cases, and failed to reach an ROC
AUC considered to be clinically relevant. These aspects
must be validated in larger multicenter studies.
Conclusions
In summary, our data reaffirm an intricate relation between
NETosis and the etiology of RA, because the signaling ele-
ments associated with NET extrusion are significantly en-
hanced to promote NETosis in RA patients compared with
healthy controls. Both ACPA-positive and -negative serumlost the ability to induce NETosis on depletion of IgG
molecules, but reconstitution of NET induction was seen
only with IgG molecules obtained from ACPA-positive
serum. The assessment of NETosis-derived products in
the sera of suspected RA cases may offer a novel comple-
mentary diagnostic tool.
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